Adaptimmune Therapeutics ADAP

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.00 (+0.00%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Adaptimmune Therapeutics (ADAP)
    Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.48

    • Market Cap

      $122.82 Million

    • Price-Earnings Ratio

      -24.00

    • Total Outstanding Shares

      1.54 Billion Shares

    • Total Employees

      449

    • Dividend

      No dividend

    • IPO Date

      May 6, 2015

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      American Depository Receipt Common

    • Headquarters

      60 jubilee avenue, Abingdon, oxfordshire, X0, OX14 4RX

    • Homepage

      https://www.adaptimmune.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$78.82 Million
    Net Cash Flow From Investing Activities, Continuing$1.08 Million
    Net Cash Flow From Operating Activities$-53.68 Million
    Net Cash Flow From Investing Activities$1.08 Million
    Net Cash Flow From Financing Activities, Continuing$78.82 Million
    Net Cash Flow, Continuing$26.22 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Basic Average Shares$4.57 Billion
    Income/Loss From Continuing Operations Before Tax$-43.29 Million
    Diluted Earnings Per Share$-0.03
    Income/Loss From Continuing Operations After Tax$-44.52 Million
    Net Income/Loss Attributable To Parent$-44.52 Million
    Basic Earnings Per Share$-0.02

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-49.75 Million
    Other Comprehensive Income/Loss Attributable To Parent$-5.24 Million
    Other Comprehensive Income/Loss$-23.19 Million
    Comprehensive Income/Loss$-50.09 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Non-current Assets$24.14 Million
    Equity$79.99 Million
    Prepaid Expenses$14.16 Million
    Fixed Assets$44.80 Million
    Liabilities And Equity$317.44 Million
    Wages$11.28 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ADAP from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.